Is ChondroFiller a safer option than cartilage surgery?

Safety is best thought of as lighter-touch versus more invasive, rather than a single yes-or-no label. Compared with operations such as microfracture or osteochondral grafting (OATS/OCA), ChondroFiller is positioned as a joint-preserving collagen scaffold approach: a cell-free type I collagen hydrogel placed into a focal cartilage defect, where it forms a temporary three-dimensional framework and is gradually resorbed as repair tissue develops. It is a CE-marked Class III medical device, not a joint replacement, and it does not contain living cells or a drug. [1]

Because it is acellular collagen, the theoretical safety profile differs from graft- or cell-based surgery. There is no donor-site wound from harvesting cartilage or osteochondral plugs (as with OATS), and no reliance on implanted donor tissue (as with osteochondral allograft), both of which come with their own sets of risks. Likewise, avoiding living-cell implantation can reduce certain immunologic and handling concerns seen with some graft-based approaches, although any intra-articular procedure can still trigger inflammation, stiffness or infection in a small proportion of cases. [1]

Early clinical safety reporting is encouraging, but limited by study size and follow-up. In a small prospective arthroscopic knee series (mean age 31), Lysholm and IKDC scores improved at 3, 6 and 12 months, and no major implant-related complications were reported over the one-year follow-up; score changes also appeared to plateau between 6 and 12 months. That kind of dataset can support a reasonable discussion about short-term recovery and tolerance, but it cannot reliably detect rare complications or define long-term durability. [1]

Longer-running evidence exists for older procedures, which is why microfracture often becomes the reference point in these comparisons: it has a much larger and longer follow-up literature than newer scaffold approaches.

In practical joint-preservation planning, the choice is often between several middle options — a scaffold approach, surgical cartilage restoration, and (in selected knees) alignment surgery to offload the damaged compartment — aimed at delaying or avoiding future joint replacement. The most defensible current position is that ChondroFiller may avoid some operation-specific risks (such as graft harvest morbidity) and appears well tolerated in small, short-term series, while remaining uncertainties centre on uncommon adverse events and outcomes beyond two to five years. [1,2]

Two delivery pathways: ChondroFiller injection and Liquid Cartilage surgery

ChondroFiller is the material — a CE-marked collagen scaffold. How it is delivered depends on the defect and the clinical context, and this is where two distinct pathways must be understood separately.

The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure. No theatre, no general anaesthetic, no incision. The scaffold is placed directly into the defect under imaging guidance and self-gels in approximately three to five minutes. This pathway suits accessible lesions and smaller joints where image-guided access is feasible, and is generally the lighter-touch option within the spectrum of cartilage care.

Liquid Cartilage is something different. It is the Lee Liquid Cartilage Protocol — Professor Paul Y. F. Lee's keyhole (arthroscopic) surgical technique that delivers the ChondroFiller scaffold alongside biological adjuncts including platelet-rich fibrin, platelet-rich plasma, and tranexamic acid, with the option of adding the patient's own mesenchymal stem cells (from bone-marrow aspirate concentrate or micro-fragmented fat) where indicated. It is genuine surgery: theatre, anaesthetic, structured rehabilitation, and peri-operative optimisation. Liquid Cartilage is the appropriate pathway for larger or load-bearing defects in the knee, hip, shoulder, or ankle where a dry arthroscopic environment and precision biological delivery are needed to support durable repair.

The distinction matters clinically. When a comparison article describes ChondroFiller as an arthroscopic procedure, that procedure is more precisely the Liquid Cartilage surgical protocol. When it describes ChondroFiller as an outpatient injection, that is the non-surgical pathway. Neither is the 'UK name' for the other — they are different modes of delivering the same scaffold, with very different clinical footprints.

What do current studies say about ChondroFiller safety and recovery?

Most published safety and recovery information for ChondroFiller comes from small studies that track two things over the first year: whether the joint tolerates the material without notable inflammatory or mechanical problems, and whether pain and function scores move in the right direction by 3, 6 and 12 months.

The clearest knee dataset comes from a small prospective arthroscopic series (mean age 31). Standard knee outcome measures (Lysholm and IKDC) improved significantly by 3 months and remained improved at 6 and 12 months, with no major implant-related complications reported during the one-year follow-up. The pattern also matters: scores did not change significantly between 6 and 12 months, suggesting that when improvement occurs it may be most noticeable in the first 3–6 months rather than continuing to climb through the full year. [1]

Outside the knee, the human literature is currently limited to small, uncontrolled reports. A hip arthroscopy case report described a 32-year-old man treated for a focal femoral head osteochondral defect, with short-term pain relief and restored function reported and no serious adverse event highlighted. Early reports in the talus similarly describe technically successful arthroscopic use with short-term clinical improvement, but without the numbers or follow-up length needed to characterise uncommon complications. [3,4]

Laboratory and animal work provides indirect reassurance on biocompatibility. In an ovine joint model using a collagen scaffold combined with an adhesive hyaluronan-based hydrogel, the construct supported cell infiltration and cartilage-like repair while preserving adjacent cartilage, with no detectable adverse reactions reported — helpful context for collagen-based scaffolds in general, even if it is not a like-for-like clinical trial. [2]

The main uncertainty is not whether short-term tolerance looks reasonable in these reports, but how far that reassurance extends. Much of the available ChondroFiller clinical evidence is based on small numbers and relatively short follow-up, which is too limited to reliably detect rare complications and too short to confirm long-term durability against established surgical options in 5–10 year terms. [1,3,4]

Can ChondroFiller help small joints like the thumb or TMJ?

Small joints (for example, the wrist and thumb base) and the temporomandibular joint (TMJ) pose different practical constraints to the knee or hip: the cartilage layer is thinner, the working space is tighter, and a small step in the joint surface can matter. A technique that looks straightforward in a larger joint does not automatically translate to a small joint without careful control of placement and thickness.

In the sources reviewed for this article, the clinical evidence base for ChondroFiller is primarily a small prospective knee series with 12-month follow-up and case-based reports describing arthroscopic application in the hip (femoral head) and ankle (talus). [1,3,4] Evidence specific to truly small joints such as the thumb CMC joint, or to TMJ osteoarthritis, is not yet established in the published literature reviewed here, and use in those joints should be treated as unproven or experimental unless supported by joint-specific clinical studies.

The non-surgical ChondroFiller injection pathway may have a role in accessible small joints where image-guided delivery is feasible, but this should be discussed on a case-by-case basis at specialist assessment, taking defect size, location, and joint mechanics into account.

Why microfracture results often fade after 2–3 years

Microfracture is commonly used as a comparator in modern cartilage-repair studies. It stimulates the formation of fibrocartilage from bone marrow — useful as a first-line measure for small defects, but biomechanically inferior to native hyaline cartilage and prone to gradual deterioration. The clinical benefits of microfracture often decline after 2–5 years, with high reoperation rates reported in some series.

In a prospective, multi-centre randomised non-inferiority trial (92 patients) comparing a biphasic cartilage repair implant with microfracture for ICRS grade 3–4 knee lesions, both groups had similar 12-month improvements in IKDC scores (meeting non-inferiority), but arthroscopic evaluation showed more fully regenerated cartilage in the implant group. [5]

At five-year follow-up in a randomised trial comparing costal chondrocyte-derived pellet-type autologous chondrocyte implantation with microfracture, both groups maintained clinical improvement, but the cell-based group had significantly higher Lysholm and KOOS scores and substantially better MOCART MRI structure scores (62.3 vs 26.7), with one treatment failure reported in the microfracture arm. [6]

Taken together, these head-to-head trials illustrate why microfracture is often seen as a useful benchmark: symptom improvement can be comparable early on, while the quality of repair tissue as assessed structurally may differ. Longer-term durability beyond the time horizons studied in these trials remains a key evidence need when choosing between options.

How ChondroFiller compares with microfracture, OATS and OCA

Choices in cartilage repair tend to fall into four mechanisms, each with a different trade-off between surgical load and long-term track record: stimulating the body to lay down repair tissue (microfracture), providing a scaffold for that repair (collagen or other matrices), swapping in real bone-and-cartilage plugs (OATS/mosaicplasty or osteochondral allograft), and implanting laboratory-prepared cartilage cells (autologous chondrocyte implantation-style procedures). In the available sources, the strongest direct comparisons are between microfracture and other implant or cell-based repairs, rather than ChondroFiller versus the main surgical benchmarks. [5,6]

Microfracture — established comparator with good short-term symptom improvement in trials

In a multicentre randomised trial, microfracture and a biphasic implant produced similar 12-month IKDC improvements, although arthroscopy suggested more complete cartilage regeneration in the implant group. The fibrocartilage formed by microfracture lacks the complex zonal organisation of native hyaline cartilage, which may explain why structural benefit can be less durable. [5]

OATS and OCA — grafting in new cartilage with surgical trade-offs

Osteochondral grafting aims to replace damaged surface-plus-foundation with a bone-cartilage plug (autograft OATS/mosaicplasty) or donor tissue (OCA). In a 66-knee cohort treated with combined high tibial osteotomy plus OATS for medial compartment osteoarthritis, Kaplan–Meier survivorship without conversion to total knee arthroplasty was reported as 96.7% at a mean of 9.49 years, with hyaline cartilage described on second-look arthroscopy in 49 of 57 knees. [7] The trade-off is donor-site morbidity with autograft, and disease transmission risk and graft availability constraints with allograft.

Cell-based repair (ACI/MACI-type) — more complex pathway with stronger medium-term structure in an RCT

In a 5-year randomised trial comparing cell-based repair with microfracture, the cell-based group had significantly higher Lysholm and KOOS scores and markedly better MRI structure scores (MOCART 62.3 vs 26.7), with one failure in the microfracture arm. The complexity trade-off is a two-stage process involving a biopsy, cell culture, and a second surgical implantation, which adds logistical burden, cost, and associated risks such as graft hypertrophy. [6]

ChondroFiller and the scaffold approach — lighter footprint but limited long-term comparative data

ChondroFiller is a CE-marked, cell-free type I collagen scaffold that supports repair without implanting living cells. Published clinical evidence includes a small prospective knee arthroscopy series and case-based reports in the hip and ankle. [1,3,4] The comparative analysis from the device's clinical evaluation report places ChondroFiller as achieving approximately 30-point IKDC improvement, broadly comparable to ACI and MACI, but from a single-stage procedure without the two-stage complexity of cell-based approaches and without the donor-site risk of OATS. [1]

The main caution is the evidence gap rather than a specific known downside: large randomised head-to-head trials of ChondroFiller versus microfracture, osteochondral grafting, or cell-based repair with long follow-up are not yet available in the published sources reviewed here. Where the surgical protocol matters, the Liquid Cartilage approach adds biological adjuncts (PRF, PRP, optional MSCs) and peri-operative optimisation to the scaffold placement — but this combined protocol's clinical evidence base is also still maturing.

A practical summary by mechanism

• Microfracture: marrow stimulation, widely used first-line comparator, RCT evidence shows meaningful short-term improvement but structural repair may be less complete than some newer approaches; clinical benefit often declines after 2–5 years. [5,6]
• ChondroFiller injection (non-surgical pathway): ultrasound-guided outpatient scaffold placement; acellular collagen hydrogel; no theatre or general anaesthetic; suited to accessible lesions and smaller joints; clinical evidence currently limited to small series. [1,3,4]
• Liquid Cartilage (surgical pathway): Professor Lee's keyhole arthroscopic protocol delivering ChondroFiller scaffold plus biological adjuncts (PRF, PRP, TXA) and optional MSCs under a dry CO2 field; theatre, anaesthetic, structured rehabilitation; designed for larger or load-bearing defects in the knee, hip, shoulder, or ankle.
• OATS/OCA (osteochondral grafting): transplants cartilage-plus-bone; higher surgical rehabilitation load; long follow-up series exist for some combined joint-preservation strategies. [7]
• Cell-based repair (ACI/MACI-type): implants cartilage-forming cells; two-stage pathway; randomised evidence at 5 years can show better structure and function than microfracture in selected knee defects. [6]

Choosing the right pathway and how LCC can help

A cartilage defect rarely exists in isolation: the same patch of damaged surface can behave very differently depending on the meniscus, ligaments, limb alignment, and how much arthritis is already present in the wider joint. Most joint-preservation plans sit on a spectrum that runs from symptom control, through biologic support and scaffold-based repair, into grafting and cell-based restoration, and only then towards joint replacement when osteoarthritis is diffuse and advanced.

In day-to-day decision-making, the key variables that tend to shift the discussion between one approach and another include: defect grade and size (Outerbridge/ICRS classification, contained versus uncontained edges); joint mechanics including limb alignment, meniscus status and ligament stability; patient context including age, occupational demands, and sport; and arthritis burden, because a focal defect in an otherwise healthy joint is a different problem from established multi-compartment osteoarthritis.

When a scaffold approach is being considered, the choice between the non-surgical ChondroFiller injection and the Liquid Cartilage surgical protocol rests on defect size, location, and accessibility. Smaller or more accessible lesions may be suited to the outpatient injection pathway. Larger, load-bearing, or anatomically complex defects — or cases where biological augmentation with MSCs is appropriate — are more likely to be addressed within the Liquid Cartilage surgical framework.

There are also clear situations where neither scaffold pathway is the primary answer. Where mechanical overload is a dominant driver — such as a varus knee with medial compartment overload — alignment correction may sit alongside cartilage work as a joint-preservation strategy. Where cartilage loss is diffuse and symptoms reflect end-stage degeneration, joint replacement is often the more realistic route than repeated attempts at focal repair.

London Cartilage Clinic, based on Harley Street as part of the MSK Doctors group, supports this kind of decision-making through a consultant-led assessment covering history, examination, and appropriate imaging (X-ray, high-quality MRI, and CT where bone detail matters), with a balanced discussion of both injection and surgical pathways. The central takeaway remains that the right option is the one that matches the defect, the mechanics, and the arthritis stage — not the newest or most invasive technique available.

References

1. IMPLANTATION OF CHONDROFILLER LIQUID AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). Journal of IMAB.
2. Collagen scaffold with adhesive hyaluronan-based hydrogel in an ovine osteochondral model: biocompatibility and repair tissue assessment.
3. Hip arthroscopy and ChondroFiller application in isolated osteochondral defect of the femoral head. (2025). Journal of Orthopaedic Case Reports.
4. Arthroscopic ChondroFiller application in osteochondral lesions of the talus: early case report series.
5. Biphasic cartilage repair implant vs microfracture for ICRS grade 3–4 knee lesions: prospective multicentre randomised non-inferiority trial (92 patients).
6. Costal chondrocyte-derived pellet-type autologous chondrocyte implantation versus microfracture for knee cartilage defects: randomised trial with 5-year follow-up.
7. Combined high tibial osteotomy and osteochondral autograft transfer for medial compartment osteoarthritis: 66-knee cohort with mean 9.49-year Kaplan-Meier survivorship analysis.